Navigation Links
Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
Date:11/1/2007

is and a growing percentage throughout the course of the

disease.

-- American Society of Hematology (ASH) Meeting -- Numerous VELCADE

abstracts are expected to be featured at the ASH meeting in December

2007. These abstracts may include data from two large, randomized

Phase III trials in patients with newly diagnosed MM. Data may also be

presented on additional VELCADE based combinations in front-line MM and

Non-Hodgkin's Lymphoma (NHL).

Clinical Pipeline Highlights

In addition to VELCADE, the Company continues to advance ten novel molecules in the areas of cancer and inflammatory diseases. Recent progress included the following:

-- MLN0002 - The Company completed enrollment in the bridging trials

designed to evaluate the safety, tolerability, pharmacokinetics and

pharmacodynamics of this novel antibody to the target alpha 4 beta 7,

derived from a new commercially scalable cell line. The Company is

tracking toward pivotal trials with MLN0002 in ulcerative colitis and

Crohn's disease.

-- MLN3897 - The Company is on track to announce top-line results for this

novel CCR1 inhibitor by year end from a 191-patient Phase II proof-of-

concept trial in rheumatoid arthritis.

-- MLN4924 - In October 2007, the Company presented data on this

Millennium-discovered molecule and target at the European Organization

for Research and Treatment of Cancer (EORTC) meeting. Data for this

inhibitor of the Nedd8-activating enzyme showed the molecule

significantly inhibited tumor growth in xenograft models for colorectal

cancer and several types of lymphoma. MLN4924 is expected to enter

Phase I trials in early 2008.

Conference Call and Presentation Reminder

Dr. Dunsire and members of the Millennium leadership team will present additional details on these results this m
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... OSAKA, Japan , April 16, 2015 ... of Kyoto University and Takeda Pharmaceutical Company Limited ... to develop clinical applications of induced pluripotent stem ... mellitus, neurological disorders and cancer immunotherapy. The "Takeda-CiRA ... designed to expedite multiple research projects for drug ...
(Date:4/16/2015)... 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... results on Thursday, April 30, 2015 at 4:00 PM ... host a conference call at 4:30 PM Eastern Time ... outlook for the future. , The conference call will ... homepage and in the Investor Relations section of Cytokinetics’ ...
(Date:4/16/2015)... Proove Biosciences , Inc. is pleased ... for the 2015 BIO International Convention. Hosted by ... Convention will take place June 15-18 at the Pennsylvania ... BIO contest, industry leaders will be voting for companies ... The community voting period began on April 14, 2015 ...
(Date:4/16/2015)... Grove, IL (PRWEB) April 16, 2015 ... the American Association for Cancer Research (AACR) annual ... the Pennsylvania Convention Center, starting Saturday, April 18, in ... AACR holds claim to title of the oldest and ... journals, provides fellowships and grants, and partners with survivors ...
Breaking Biology Technology:CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3Regis Technologies Joins American Association for Cancer Research Annual Meeting 2
... NEW YORK, Dec. 17 In its second annual ... rising,young scientists who are making an impact early in ... large-scale biomedical research through the,eyes of some of the ... contributions to their areas of interest., The young ...
... Chief Technology Officer, MENLO PARK, Calif., Dec. ... commercializing a patented,proprietary sensor technology platform having applications ... announced today that Robin C.,Stracey has joined the ... 17, 2007. He has also been appointed to ...
... Pilot Chevrolet Car, VALLEY FORGE, Pa., Dec. 17 ... joined with Diversified Racing Solutions,(DRS) to enter the NASCAR(R) ... the NASCAR Sprint Cup Series in 2010. In the ... the flagship,sponsor; the venture will be primarily funded by ...
Cached Biology Technology:Genome Technology Magazine Names Top Young Investigators of 2007 2Robin C. Stracey Joins Cantimer, Inc. as President and CEO 2Good Neighbor Pharmacy Joins with Diversified Racing Solutions to Enter NASCAR Nationwide Series in 2008 2
(Date:4/13/2015)... 13, 2015 According to ... Biometrics Market Forecast & Opportunities, 2020", the global biometrics ... around 14% till 2020. The biometrics market is ... implementation and review of biometric management systems. The ... products with greater efficiency, are resulting in increasing ...
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:4/2/2015)... 2015 In the current ... outperforms the strongest competitors, showing outstanding performance in ... system is capable of a throughput of 5.000.000 ... to be ten times faster than most competitors ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... 17, 2009 Time and time again, it has been ... risks associated with the comorbidities of obesity. With only ... Institutes of Health exercise guidelines of 300 minutes/week, a study ... Nutrition Education and Behavior explores the paradox that exists ...
... Maternal behavior itself can trigger the development of new ... female was pregnant or has nursed, according to a ... of Veterinary Medicine. These findings performed in adult, virgin ... and are available online at http://dx.doi.org/10.1016/j.brainresbull.2009.08.011 . ...
... possible to use therapeutic vaccines to create both cheap and ... in developing such vaccines has previously been the lack of ... now been a major breakthrough in this area. The study, ... December issue of the journal Vaccine . Many ...
Cached Biology News:Negative emotions outweigh intent to exercise at health clubs 2Exposure to young triggers new neuron creation in females exhibiting maternal behavior 2Major breakthrough may pave the way for therapeutic vaccines 2
... Human Pathogenic Viruses The National ... preserves well characterised, authenticated human ... facility, and NCPV is able ... nucleic acids derived from them, ...
... 5 Fluorescein 6-Fam, Hex, ... 3 Fluorescein Tamra Black Hole ... 6-Fam, Hex, Tet Tamra, Joe ... Health Research Institute, New York Double labelled ...
... flexible and easy to use ... control all members of the ... features a clear and easy-to-follow ... setup, user-friendly and highly sophisticated ...
... is a highly purified preparation of the ... protease which recognizes the identical cleavage site ... similar enzymatic activity (1). Novagen&'s enzyme is ... yield the highest activity available, and is ...
Biology Products: